Prolactin, subjective well-being and sexual dysfunction: An open label observational study comparing quetiapine with risperidone

Journal of Sexual Medicine

Volumn 5, Issue 12, 2008, Pages 2816-2826

  Westheide, Jens ^a   Cvetanovska, Gabriele ^a   Albrecht, Carsten ^b   Bliesener, Niclaas ^a   Cooper Mahkorn, Déirdre ^a   Creutz, Cornelia ^b   Hornung, Wolfgang Peter ^b   Klingmüller, Dietrich ^a   Lemke, Matthias R ^b   Maier, Wolfgang ^a   Schubert, Michaela ^b   Sträter, Birgitta ^a   Kühn, Kai Uwe ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Rhine Clinic Bonn   (Germany)

Author keywords

Prolactin; Quetiapine; Risperidone; Schizophrenia; Sexual Dysfunction

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; QUETIAPINE; RISPERIDONE; TESTOSTERONE;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMOTIONALITY; FEMALE; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; ORGASM DISORDER; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; WELLBEING;

EID: 57449089926     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00859.x     Document Type: Article

References (41)

1. Westheide J, Cohen S, Bender S, Cooper-Mahkorn D, Erfurth A, Gastpar M, Huber TJ, Maier W, Murafi A, Rothermund M, Signerski J, Strater B, Teusch L, Weig W, Welling A, Kuhn KU. Sexual dysfunction in psychiatric inpatients. The role of antipsychotic medication. Pharmacopsychiatry 2007; 40: 140-5.
2. Westheide J, Helmstaedter C, Cooper-Mahkorn D, Strater B, Maier W, Kuhn KU. Sexuality in male psychiatric inpatients. A descriptive comparison of psychiatric patients, patients with epilepsy and healthy volunteers. Pharmacopsychiatry 2007; 40: 183-90.
3. Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. Sex J Marital Ther 2006; 32: 315-26.
4. Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther 2003; 29: 125-47.
5. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003; 28 (1 suppl): 69-82.
6. Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004; 20: 189-97.
7. Byerly MJ, Nakonezny PA, Bettcher BM, Carmody T, Fisher R, Rush AJ. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006; 86: 244-50.
8. Dickson RA, Glazer WM. Hyperprolactinemia and male sexual dysfunction. J Clin Psychiatry 1999; 60: 125.
9. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: Impact on prolactin levels. Expert Opin Pharmacother 2002; 3: 1381-91.
10. Tenback DE, van Harten PN, Slooff CJ, van Os J. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 2006; 31: 1832-7.
11. Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006; 31: 340-6.
12. Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G, Petrone L, Forti G, Maggi M. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med 2007; 4: 1485-93.
13. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A, Shakhnovich T, Akram A, Pecenak J, McBride M, Treuer T. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006; 21: 251-8.
14. Maguire GA. Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 (4 suppl): 56-62.
15. Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63: 408-13.
16. Naber D. Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2. Auflage. Uni-Med: Bremen; 2000.
17. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Improvement of schizophrenic patients'subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79-88.
18. El-Sakka AI. Association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med 2007; 4: 1691-700.
19. Parish WL, Laumann EO, Pan S, Hao Y. Sexual dysfunctions in urban china: A population-based national survey of men and women. J Sex Med 2007; 4: 1559-74.
20. Ricci E, Parazzini F, Mirone V, Imbimbo C, Palmieri A, Bortolotti A, Di Cintio E, Landoni M, Lavezzari M. Current drug use as risk factor for erectile dysfunction: Results from an Italian epidemiological study. Int J Impot Res 2003; 15: 221-4.
21. Hafez ES, Hafez SD. Erectile dysfunction: Anatomical parameters, etiology, diagnosis, and therapy. Arch Androl 2005; 51: 15-31.
22. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000; 57: 1012-30.
23. Rourke C, Starr KR, Reavill C, Fenwick S, Deadman K, Jones DN. Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: A comparison with clinical data. Psychopharmacology (Berl) 2006; 184: 107-14.
24. Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007; 33: 203-16.
25. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19: 57-61.
26. Byerly MJ, Lescouflair E, Weber MT, Bugno RM, Fisher R, Carmody T, Varghese F, Rush AJ. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther 2004; 30: 325-32.
27. Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, van den Bosch RJ. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004; 24: 56-61.
28. Cohen S, Kuhn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Rothermundt M, Signerski J, Strater B, Teusch L, Weig W, Welling A, Westheide J, Huber TJ. Sexual impairment in psychiatric inpatients: Focus on depression. Pharmacopsychiatry 2007; 40: 58-63.
29. Ko YH, Jung SW, Joe SH, Lee CH, Jung HG, Jung IK, Kim SH, Lee MS. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizo phrenia. Psychoneuroendocrinology 2007; 32: 385-91.
30. Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res 2006; 84: 405-10.
31. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007; 37: 1427-36.
32. Magharious W, Goff DC, Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res 1998; 77: 159-66.
33. Spollen JJ 3rd, Wooten RG, Cargile C, Bartztokis G. Prolactin levels and erectile function in patients treated with risperidone. J Clin Psychopharmacol 2004; 24: 161-6.
34. Mann K, Rossbach W, Muller MJ, Muller-Siecheneder F, Pott T, Linde I, Dittmann RW, Hiemke C. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006; 31: 256-64.
35. Cohen S, Huber TJ. Stichtagserhebung zu Störungen der Sexualität bei stationär behandelten, psy chisch kranken Menschen. Nervenarzt 2006; 77: S -326.
36. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 (3 suppl): 133-8.
37. Naber D. Atypical antipsychotics. Nervenarzt 2000; 71: 327-8.
38. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988; 23: 99-110.
39. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28 (2 suppl): 69-82.
40. Rinieris P, Hatzimanolis J, Markianos M, Stefanis C. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients. Neuropsychobiology 1989; 22: 146-9.
41. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006; 67: 1093-103.